Stockscreener 앱 받기
1.48
3.27%
-0.05
시장 영업 전:
1.49
0.01
+0.68%
전일 마감가:
$1.53
열려 있는:
$1.53
하루 거래량:
5.77M
Relative Volume:
0.75
시가총액:
$501.01M
수익:
$4.47M
순이익/손실:
$-71.67M
주가수익비율:
-6.3848
EPS:
-0.2318
순현금흐름:
$-59.58M
1주 성능:
+6.47%
1개월 성능:
+8.03%
6개월 성능:
+9.63%
1년 성능:
+60.16%
1일 변동 폭
$1.48
$1.56
1주일 범위
$1.36
$1.6899
52주 변동 폭
$0.9029
$2.725
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.48 | 517.94M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
498.01 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
624.72 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
909.50 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.67 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.51 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Canaccord Genuity | Buy |
| 2026-03-11 | 개시 | Oppenheimer | Outperform |
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen to Participate in Upcoming July Industry Conferences - The Manila Times
Ocugen’s July retina conference talks include OCU410 phase 2 results - Stock Titan
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen, Inc. pursues gene therapy innovation to address rare vision loss conditions - Traders Union
Why Did OCGN Stock Rise Today? - Stocktwits
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 2500 Growth Benchmark - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 2000 Index - marketscreener.com
OCGN Stock Grinds Higher As Traders Track Tight Range - StocksToTrade
Ocugen’s CFO Makes a Rare Open-Market Buy as Institutional Investors Pile In Ahead of Key Gene The - AD HOC NEWS
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 2000 Value Benchmark - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell Microcap Value Benchmark Index - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 3000E Growth Benchmark - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell Microcap Index - marketscreener.com
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
OCGN Stock Holds Buy Rating As Analyst Sees Key Catalysts Ahead - StocksToTrade
Enterprise value to EBITDA forward of Ocugen, Inc. – NASDAQ:OCGN - TradingView
Has Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Future - Kavout | AI
Price to book forward of Ocugen, Inc. – NASDAQ:OCGN - TradingView
Ocugen Inc Actuals & Estimates (NASDAQ:OCGN) - TradingView
Price to book forward of Ocugen Inc – SWB:2H51 - TradingView
Ocugen Inc (OCGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to revenue forward of Ocugen, Inc. – NASDAQ:OCGN - TradingView
Ocugen's gene-agnostic eye therapies could reshape late-stage care - MSN
Price to earnings forward of Ocugen, Inc. – NASDAQ:OCGN - TradingView
Price to sales forward of Ocugen Inc – SWB:2H51 - TradingView
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Enterprise value to EBIT forward of Ocugen Inc – SWB:2H51 - TradingView
Price to earnings forward of Ocugen Inc – SWB:2H51 - TradingView
OCGN Forecast — Price Target — Prediction for 2027 - TradingView
Ocugen (OCGN) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Ocugen: Financing Risk Is Lower, But The Clinical Bet Still Has To Work - Seeking Alpha
Ocugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst View - Yahoo Finance
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data - Stocktwits
Ocugen Inc (OCGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
OCGN Stock Holds Buy Rating As Analyst Trims Price Target - StocksToTrade
Ocugen completes OCU400 Phase 3 enrollment, shares trade in tight NASDAQ range - Ad-hoc-news.de
Ocugen StockFriday review and biotech sector context - AD HOC NEWS
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Inc (OCGN) Institutional Confidence - TradingKey
Ocugen Inc (OCGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ocugen Inc (OCGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ocugen Inc (OCGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ocugen Inc (OCGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ocugen Inc (OCGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ocugen, Inc. leadership drives focus on innovative gene therapies at industry summit - Traders Union
Ocugen’s Shares Leap 32% Post Oppenheimer’s Positive Coverage - timothysykes.com
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
0.52%
자본화:
|
볼륨(24시간):